Anna Boron, MD
Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1548445182
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Abbott at 28.5% of the total. Reporting peaked in 2021 at $12,433 and has fallen 75.8% since, to $3,003 in 2025. Among endocrinology, diabetes & metabolism clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 863 payments — averaging $37.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Corcept Therapeutics$6K
- Novo Nordisk$3K
- Lilly USA, LLC$1K
- Amgen$1K
- Boehringer Ingelheim$985
- plus $11K from 54 others
What the payments were for
- Consulting fees$4,22013%
- Speaking & faculty fees$10,06331%
- Travel & lodging$3281%
- Food & beverage$17,56654%
- Education$900%
- Gifts$1781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre Pro$6,475
- Korlym$4,766
- FreeStyle Libre 2$1,971
- RYBELSUS$1,620
- FreeStyle Libre$476
- CeQur Simplicity$129
- EVENITY$128
- Ozempic$125
How this compares
$32,445 in reported general payments places this provider in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CrysvitaBurosumab-Twza | 15 | $600,989 |
| OzempicSemaglutide | 247 | $483,512 |
| KorlymMifepristone | 11 | $356,501 |
| MounjaroTirzepatide | 235 | $312,414 |
| TrulicityDulaglutide | 121 | $156,305 |
| JardianceEmpagliflozin | 125 | $152,477 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 103 | $151,191 |
| FarxigaDapagliflozin Propanediol | 111 | $121,957 |
| Nutropin Aq NuspinSomatropin | 11 | $51,318 |
| GenotropinSomatropin | 14 | $44,806 |
| KerendiaFinerenone | 32 | $42,875 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 12 | $29,767 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $29,472 |
| ProliaDenosumab | 15 | $26,507 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $26,047 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kyowa Kirin, Inc.Crysvita | $29 | $600,98915 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $3,053 | $526,747290 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,484 | $484,598418 claims |
| Corcept TherapeuticsKorlym | $5,636 | $356,50111 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $985 | $167,391140 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $516 | $151,191103 claims |
| AstraZenecaFarxiga | $696 | $121,957111 claims |
| AmgenEvenity (2 Syringes), Prolia | $1,147 | $56,27427 claims |
| PfizerGenotropin, Eliquis | $80 | $51,69826 claims |
| BayerKerendia | $240 | $42,87532 claims |
| AbbVieSynthroid | $917 | $16,833183 claims |
| Cequr CorporationCequr Simplicity | $187 | $7,90018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Phoenix
- Kevin YuenPhoenix$404K
- Joan BaileyPhoenix$316K
- Kari EdlingPhoenix$23K
- James DeerPhoenix$13K
- Lory BarazPhoenix$10K
- Sathya JyothinagaramPhoenix$10K
- Philip LevyPhoenix$9K
- Richard ArakakiPhoenix$6K
- Yasmin AkhunjiPhoenix$5K
- Ahmad Al MaradniPhoenix$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.